Ad
Thursday, 23 November 2017
Bayer pharmaceuticals head says there's no pipeline problem
LEVERKUSEN, Germany (Reuters) - Bayer is seeking to defend its pharmaceuticals business that will be diluted in importance by the takeover of Monsanto and faces a threat to revenues in 2024 when the blockbuster heart drug Xarelto loses its patent.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment